Main logo
tutorial arrow
Create your own tool library
Bookmark tools and put favorites into folders to find them easily.



A resource of signal transduction pathways in humans. NetPath provides detailed maps of a number of immune signalling pathways, which include approximately 1600 reactions annotated from the literature and more than 2800 instances of transcriptionally regulated genes, all linked to over 5500 published articles. NetPath allows biomedical scientists to visualize, process and manipulate data pertaining to signalling pathways in humans.

User report

tutorial arrow
Vote up tools and offer feedback
Give value to tools and make your expertise visible
Give your feedback on this tool
Sign up for free to join and share with the community

0 user reviews

0 user reviews

No review has been posted.

NetPath forum

tutorial arrow
Communicate with other users
Participate in the forum to get support for using tools. Ask questions about technical specifications.
Take part in the discussion
Sign up for free to ask question and share your advices

No open topic.

NetPath classification

NetPath specifications

Restrictions to use:
Data access:
File download, Application programming interface

NetPath distribution

NetPath support


  • Akhilesh Pandey <>


tutorial arrow
Promote your skills
Define all the tasks you managed and assign your profile the appropriate badges. Become an active member.
Promote your work
Sign up for free to badge your contributorship



Institute of Bioinformatics, International Tech Park, Bangalore, India; McKusick-Nathans Institute of Genetic Medicine and the Department of Biological Chemistry, Johns Hopkins University, Baltimore, MD, USA; Research Unit for Immunoinformatics, RIKEN Research Center for Allergy and Immunology, RIKEN Yokohama Institute, Kanagawa, Japan; Department of Biotechnology and Bioinformatics, Kuvempu University, Jnanasahyadri, Shimoga, India; Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA; Department of Microbiology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA; Department of Molecular Biology and Genetics, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The Ludwig Institute for Cancer Research, Brussels Branch, and the Experimental Medicine Unit, Christian de Duve Institute of Cellular Pathology, Universite Catholique de Louvain, Brussels, Belgium; Laboratory for Immunogenomics, RIKEN Research Center for Allergy and Immunology, RIKEN Yokohama Institute, Kanagawa, Japan; Department of Human Genome Technology, Kazusa DNA Research Institute, Kazusa-Kamatari, Kisarazu, Chiba, Japan; Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology, Yokohama, Kanagawa, Japan; Laboratories of Developmental Immunology, Graduate School of Frontier Biosciences and Graduate School of Medicine, Osaka University, Osaka, Japan; Research Institute for Biological Sciences, Tokyo University of Science, Yamazaki, Noda City, Chiba, Japan; Signal/Network Team, RIKEN Research Center for Allergy and Immunology, RIKEN Yokohama Institute, Suehiro-cho, Tsurumi, Yokohama, Kanagawa, Japan; IMGENEX India Pvt. Ltd., Bhubaneswar, Orissa, India; Department of Computer Science, Wayne State University, Detroit, MI, USA; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA; Banting and Best Department of Medical Research, Terrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada; Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Oncology, Johns Hopkins University, Baltimore, MD, USA

Funding source(s)

This work was supported by the Johns Hopkins Breast Cancer SPORE (grant n°CA 88843) Career Development Award, the Department of Defense Era of Hope Scholar (grant n°W81XWH-06-1-0428) and the National Institutes of Health (grant n°U54 RR020839).

Link to literature

By using OMICtools you acknowledge that you have read and accepted the terms of the end user license agreement.